PRMA Consulting’s Nicole Lodowski in a recent blog post outlines seven key areas that have been updated in the Institute for Clinical and Economic Review’s (ICER) value assessment framework.
According to the post, here are three of the seven key updates by ICER:
- Enhancing commitment to the use of real-world evidence within product and therapeutic assessments;
- Amending the ICER voting structure to further capture other benefits and contextual considerations; and
- Further defining patient subpopulations where treatments may provide differential benefits.
To read the full blog post, click here.